LinkedIn Profile

Access PrognosDx Health historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:prognosdxhealth 1307285 May 31st, 2019 12:00AM PrognosDx Health 89 1.00 Open Biotechnology May 31st, 2019 02:59AM May 31st, 2019 02:59AM PrognosDx is a biotechnology company committed to eliminating the trial and error approach to cancer treatment through analysis of global histone modifications, powerful master switches of the genome and gatekeepers to aggressive tumor metabolism that reveal critical information about aggressiveness of disease or potential to respond to specific types of treatment. This revolutionary epigenetic technology in the short-term can help physicians personalize patient treatments by identifying molecular signatures specific to each patient’s tumor cells and in the long run revolutionizes drug development by targeting aggressive cancer cells. Based on four published international clinical studies, the company is currently aimed at clinical development of its PrognoScore™ laboratory test to help prostate cancer patients and their treating physicians select appropriate personalized treatments leading to improved patient outcomes while reducing overall healthcare costs. Originally developed at UCLA, PrognoScore™ addresses the shortcomings of routine tests such as pre-operative PSA or inconclusive Gleason scores by correctly identifying men with non-life threatening forms of prostate cancer who may benefit from avoiding unnecessary treatments including radiation and surgery. Open Cancer Prognostication, Cancer drug response prediction, Aggressive cancer cell targetted drug development, Oncology Open 530 University Ave, Mail Box 203 Palo Alto CA US 94301 PrognosDx Health Health Care Equipment & Services
private:prognosdxhealth 1307285 Nov 7th, 2017 12:00AM PrognosDx Health 83 0.00 Open Biotechnology Nov 7th, 2017 05:06PM Nov 7th, 2017 05:06PM PrognosDx is a biotechnology company committed to eliminating the trial and error approach to cancer treatment through analysis of global histone modifications, powerful master switches of the genome and gatekeepers to aggressive tumor metabolism that reveal critical information about aggressiveness of disease or potential to respond to specific types of treatment. This revolutionary epigenetic technology in the short-term can help physicians personalize patient treatments by identifying molecular signatures specific to each patient’s tumor cells and in the long run revolutionizes drug development by targeting aggressive cancer cells. Based on four published international clinical studies, the company is currently aimed at clinical development of its PrognoScore™ laboratory test to help prostate cancer patients and their treating physicians select appropriate personalized treatments leading to improved patient outcomes while reducing overall healthcare costs. Originally developed at UCLA, PrognoScore™ addresses the shortcomings of routine tests such as pre-operative PSA or inconclusive Gleason scores by correctly identifying men with non-life threatening forms of prostate cancer who may benefit from avoiding unnecessary treatments including radiation and surgery. PrognosDx Health Health Care Equipment & Services
private:prognosdxhealth 1307285 Nov 1st, 2017 12:00AM PrognosDx Health 83 0.00 Open Biotechnology Nov 1st, 2017 04:52AM Nov 1st, 2017 04:52AM PrognosDx is a biotechnology company committed to eliminating the trial and error approach to cancer treatment through analysis of global histone modifications, powerful master switches of the genome and gatekeepers to aggressive tumor metabolism that reveal critical information about aggressiveness of disease or potential to respond to specific types of treatment. This revolutionary epigenetic technology in the short-term can help physicians personalize patient treatments by identifying molecular signatures specific to each patient’s tumor cells and in the long run revolutionizes drug development by targeting aggressive cancer cells. Based on four published international clinical studies, the company is currently aimed at clinical development of its PrognoScore™ laboratory test to help prostate cancer patients and their treating physicians select appropriate personalized treatments leading to improved patient outcomes while reducing overall healthcare costs. Originally developed at UCLA, PrognoScore™ addresses the shortcomings of routine tests such as pre-operative PSA or inconclusive Gleason scores by correctly identifying men with non-life threatening forms of prostate cancer who may benefit from avoiding unnecessary treatments including radiation and surgery. PrognosDx Health Health Care Equipment & Services

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.